EurekaMag.com logo
+ Site Statistics
References:
52,725,316
Abstracts:
28,411,598
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

RTOG study 0324: Cetuximab in combination with chemoradiation in patients with stage IIIA/B non-small-cell lung cancer






Strahlentherapie und Onkologie 188(2): 194-195

RTOG study 0324: Cetuximab in combination with chemoradiation in patients with stage IIIA/B non-small-cell lung cancer



Accession: 055338942

PMID: 22218504

DOI: 10.1007/s00066-011-0034-7



Related references

Phase II study of cetuximab in combination with chemoradiation in patients with stage IIIA/B non-small-cell lung cancer: RTOG 0324. Journal of Clinical Oncology 29(17): 2312-2318, 2011

A phase II study of cetuximab (C225) in combination with chemoradiation (CRT) in patients (PTS) with stage IIIA/B non-small cell lung cancer (NSCLC): An interim overall toxicity report of the RTOG 0324 Trial. Journal of Clinical Oncology 23(16_suppl): 7135-7135, 2016

RTOG 0324: A phase II study of cetuximab (C225) in combination with chemoradiation (CRT) in patients (PTS) with stage IIIA/B non-small cell lung cancer (NSCLC): Correlation between EGFR expression and the patients' outcome. International Journal of Radiation Oncology*Biology*Physics 69(3-supp-S): 0-0, 2007

A phase II study of cetuximab (C225) in combination with chemoradiation (CRT) in patients (PTS) with stage IIIA/B non-small cell lung cancer (NSCLC): A report of the 2 year and median survival (MS) for the RTOG 0324 trial. Journal of Clinical Oncology 26(15_suppl): 7516-7516, 2016

RTOG 0324: A phase II study of cetuximab (C225) in combination with chemoradiation (CRT) in patients with stage IIIA/B non-small cell lung cancer (NSCLC)-Association between EGFR gene copy number and patients' outcome. Journal of Clinical Oncology 26(15_suppl): 7607-7607, 2016

EGFR expression and survival in patients given cetuximab and chemoradiation for stage III non-small cell lung cancer: a secondary analysis of RTOG 0324. RadioTherapy and Oncology 112(1): 30-36, 2015

Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Lancet. Oncology 16(2): 187-199, 2015

Phase II pilot study of neoadjuvant cetuximab in combination with cisplatin and gemcitabine in patients with resectable IB-IIIA non small cell lung cancer. Journal of Clinical Oncology 24(18_suppl): 17107-17107, 2016

Randomized phase II study of amifostine mucosal protection by either subcutaneous injection or rapid IV bolus for patients with inoperable stage II-IIIA/B or stage IV non-small cell lung cancer with oligometastases receiving concurrent radiochemotherapy with carboplatin and paclitaxel followed by optional consolidative chemotherapy: a follow-up study after RTOG 98-01. Seminars in Oncology 31(6 Suppl 18): 47-51, 2005

The effects of comorbidity and age on RTOG study enrollment in Stage III non-small cell lung cancer patients who are eligible for RTOG studies. International Journal of Radiation Oncology, Biology, Physics 78(5): 1394-1399, 2010